NeuroVive Pharmaceutical AB Price/Sales
What is the Price/Sales of NeuroVive Pharmaceutical AB?
The Price/Sales of NeuroVive Pharmaceutical AB is 2,313.89
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with price/sales similar to NeuroVive Pharmaceutical AB
- Shyam Telecom has Price/Sales of 2,185.00
- Security Matters has Price/Sales of 2,220.12
- Feedback plc has Price/Sales of 2,226.78
- Oil Country Tubular has Price/Sales of 2,264.86
- Pantheon Resources Plc has Price/Sales of 2,277.12
- Cardinal Resources has Price/Sales of 2,301.61
- NeuroVive Pharmaceutical AB has Price/Sales of 2,313.89
- Silver City Minerals has Price/Sales of 2,337.84
- Jericho Oil has Price/Sales of 2,350.98
- Ecolomondo has Price/Sales of 2,351.27
- Harfang Exploration has Price/Sales of 2,359.22
- Revolution Medicines Inc has Price/Sales of 2,384.40
- Apollo Minerals has Price/Sales of 2,406.36